{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:19:00Z","timestamp":1791497940681,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00277-025-06543-3","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T05:59:32Z","timestamp":1756533572000},"page":"4505-4514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes"],"prefix":"10.1007","volume":"104","author":[{"given":"Antonio","family":"Sanz-Solas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Saiz-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Calvo","family":"Simal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Rodr\u00edguez-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Solana-Altabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Labrador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"issue":"3","key":"6543_CR1","first-page":"38","volume":"103","author":"A Pelcovits","year":"2020","unstructured":"Pelcovits A, Niroula R (2020) Acute myeloid leukemia: A review. R I Med J (2013) 103(3):38\u201340","journal-title":"R I Med J (2013)"},{"key":"6543_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (2019) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 36:70\u201387","journal-title":"Blood Rev"},{"issue":"1","key":"6543_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","volume":"27","author":"T B\u00fcchner","year":"2009","unstructured":"B\u00fcchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, M\u00fcller-Tidow C et al (2009) Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German acute myeloid leukemia cooperative group. J Clin Oncol 27(1):61\u201369","journal-title":"J Clin Oncol"},{"issue":"6","key":"6543_CR4","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41375-020-01058-4","volume":"35","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2021","unstructured":"Mart\u00ednez-Cuadr\u00f3n D, Serrano J, Gil C, Tormo M, Mart\u00ednez-S\u00e1nchez P, P\u00e9rez-Sim\u00f3n JA et al (2021) Evolving treatment patterns and outcomes in older patients (\u2265 60 years) with AML: changing everything to change nothing? Leukemia 35(6):1571\u20131585","journal-title":"Leukemia"},{"issue":"4","key":"6543_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447","journal-title":"Blood"},{"issue":"4","key":"6543_CR6","first-page":"485","volume":"57","author":"JW Yates","year":"1973","unstructured":"Yates JW, Wallace HJ, Ellison RR, Holland JF (1973) Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 57(4):485\u2013488","journal-title":"Cancer Chemother Rep"},{"issue":"3","key":"6543_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126(3):291\u2013299","journal-title":"Blood"},{"issue":"12","key":"6543_CR8","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/cncr.33403","volume":"127","author":"S Vives","year":"2021","unstructured":"Vives S, Mart\u00ednez-Cuadr\u00f3n D, Bergua Burgues J, Algarra L, Tormo M, Mart\u00ednez-S\u00e1nchez MP et al (2021) A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Cancer 127(12):2003\u20132014","journal-title":"Cancer"},{"issue":"21","key":"6543_CR9","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670\u20132677","journal-title":"J Clin Oncol"},{"issue":"1","key":"6543_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317","journal-title":"Blood"},{"issue":"7","key":"6543_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"17","key":"6543_CR12","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","volume":"119","author":"G Juliusson","year":"2012","unstructured":"Juliusson G, Lazarevic V, H\u00f6rstedt AS, Hagberg O, H\u00f6glund M, for the Swedish Acute Leukemia Registry Group (2012) Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 119(17):3890\u20133899","journal-title":"Blood"},{"issue":"3","key":"6543_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/hon.851","volume":"26","author":"AM Tsimberidou","year":"2008","unstructured":"Tsimberidou AM, Estey E (2008) Relevance of clinical trials in acute myeloid leukaemia. Hematol Oncol 26(3):182\u2013183","journal-title":"Hematol Oncol"},{"issue":"22","key":"6543_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225677","volume":"13","author":"M Saiz-Rodr\u00edguez","year":"2021","unstructured":"Saiz-Rodr\u00edguez M, Labrador J, Cuevas B, Mart\u00ednez-Cuadr\u00f3n D, Campuzano V, Alcaraz R et al (2021) Use of azacitidine or decitabine for the up-front setting in acute myeloid leukaemia: a systematic review and meta-analysis. Cancers (Basel) 13(22):5677","journal-title":"Cancers (Basel)"},{"key":"6543_CR15","unstructured":"citing abstrackr [Internet] [cited 2024 Feb 9]. Available from: http:\/\/abstrackr.cebm.brown.edu\/citing\/"},{"key":"6543_CR16","unstructured":"Chapter 8 Assessing risk of bias in a randomized trial [Internet]. [cited 2024 Apr 5]. Available from: https:\/\/training.cochrane.org\/handbook\/current\/chapter-08"},{"issue":"1","key":"6543_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","volume":"72","author":"VN Nyaga","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M (2014) Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 72(1):39","journal-title":"Arch Public Health"},{"issue":"1","key":"6543_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5(1):13","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"6543_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V et al (2021) Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol 96(2):208\u2013217","journal-title":"Am J Hematol"},{"issue":"2","key":"6543_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M et al (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19(2):216\u2013228","journal-title":"Lancet Oncol"},{"key":"6543_CR21","doi-asserted-by":"publisher","first-page":"858202","DOI":"10.3389\/fonc.2022.858202","volume":"12","author":"MK Mustafa Ali","year":"2022","unstructured":"Mustafa Ali MK, Corley EM, Alharthy H, Kline KAF, Law JY, Lee ST et al (2022) Outcomes of newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: A propensity Score-Adjusted cohort study. Front Oncol 12:858202","journal-title":"Front Oncol"},{"issue":"12","key":"6543_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41408-022-00770-x","volume":"12","author":"D Kwag","year":"2022","unstructured":"Kwag D, Cho BS, Bang SY, Lee JH, Min GJ, Park SS et al (2022) Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer J 12(12):169","journal-title":"Blood Cancer J"},{"key":"6543_CR23","doi-asserted-by":"publisher","first-page":"748766","DOI":"10.3389\/fphar.2021.748766","volume":"12","author":"L Gozzo","year":"2021","unstructured":"Gozzo L, Vetro C, Brancati S, Longo L, Vitale DC, Romano GL et al (2021) Off-label use of venetoclax in patients with acute myeloid leukemia: single center experience and data from pharmacovigilance database. Front Pharmacol 12:748766","journal-title":"Front Pharmacol"},{"issue":"24","key":"6543_CR24","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J et al (2021) Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Advances 5(24):5565\u20135573","journal-title":"Blood Advances"},{"issue":"1","key":"6543_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyab170","volume":"52","author":"K Yamamoto","year":"2022","unstructured":"Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T et al (2022) Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J Clin Oncol 52(1):29\u201338","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"6543_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","volume":"8","author":"A Bataller","year":"2023","unstructured":"Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG et al (2023) Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927\u2013935","journal-title":"Blood Adv"},{"issue":"3","key":"6543_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","volume":"102","author":"M Aiba","year":"2023","unstructured":"Aiba M, Shigematsu A, Suzuki T, Miyagishima T (2023) Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol 102(3):541\u2013546","journal-title":"Ann Hematol"},{"issue":"13","key":"6543_CR28","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, DiNardo CD, Arellano ML, Pigneux A, Fiedler W, Konopleva M et al (2022) Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations. Clin Cancer Res 28(13):2753\u20132761","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6543_CR29","first-page":"1006","volume":"108","author":"CE Jensen","year":"2023","unstructured":"Jensen CE, Heiling HM, Beke KE, Deal AM, Bryant AL, Coombs LA et al (2023) Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens. Haematologica 108(4):1006\u20131014","journal-title":"Haematologica"},{"issue":"5","key":"6543_CR30","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1016\/j.clml.2023.02.002","volume":"23","author":"A Gershon","year":"2023","unstructured":"Gershon A, Ma E, Xu T, Montez M, Naqvi K, Ku G et al (2023) Early real-world first-line treatment with venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominately US community setting. Clin Lymphoma Myeloma Leuk 23(5):e222\u2013e231","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6543_CR31","unstructured":"Retrospective real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy - PubMed [Internet]. [cited 2024 May 14]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36482507\/"},{"issue":"3","key":"6543_CR32","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/CAD.0000000000001431","volume":"34","author":"RH Hu","year":"2023","unstructured":"Hu RH, Su L, Lan XX, Chang XL, Hui WH, Guo YX et al (2023) A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia. Anticancer Drugs 34(3):344\u2013350","journal-title":"Anticancer Drugs"},{"issue":"15","key":"6543_CR33","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.3390\/cancers14153576","volume":"14","author":"SY Ong","year":"2022","unstructured":"Ong SY, Tan Si Yun M, Abdul Halim NA, Christopher D, Jen WY, Gallardo C et al (2022) Real-World experience of measurable residual disease response and prognosis in acute myeloid leukemia treated with venetoclax and Azacitidine. Cancers (Basel) 14(15):3576","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6543_CR34","first-page":"331","volume":"9","author":"V Karakus","year":"2022","unstructured":"Karakus V, Maral S, Kaya E, Gemici A, Dere Y, Sevindik OG (2022) Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: real experience data. North Clin Istanb 9(4):331\u2013336","journal-title":"North Clin Istanb"},{"issue":"9","key":"6543_CR35","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3390\/cancers14092342","volume":"14","author":"J Labrador","year":"2022","unstructured":"Labrador J, Mart\u00ednez-Cuadr\u00f3n D, de la Fuente A, Rodr\u00edguez-Veiga R, Serrano J, Tormo M et al (2022) Azacitidine vs. Decitabine in unfit newly diagnosed acute myeloid leukemia patients: results from the PETHEMA registry. Cancers (Basel) 14(9):2342","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6543_CR36","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41375-021-01425-9","volume":"36","author":"C R\u00e9cher","year":"2022","unstructured":"R\u00e9cher C, R\u00f6llig C, B\u00e9rard E, Bertoli S, Dumas PY, Tavitian S et al (2022) Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia 36(4):913\u2013922","journal-title":"Leukemia"},{"issue":"4","key":"6543_CR37","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1080\/10428194.2021.2002321","volume":"63","author":"T Miyamoto","year":"2022","unstructured":"Miyamoto T, Sanford D, Tomuleasa C, Hsiao HH, Olivera LJE, Enjeti AK et al (2022) Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy. Leuk Lymphoma 63(4):928\u2013938","journal-title":"Leuk Lymphoma"},{"key":"6543_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05891-w","author":"A Solana-Altabella","year":"2024","unstructured":"Solana-Altabella A, Rodr\u00edguez-Veiga R, Mart\u00ednez-Cuadr\u00f3n D, Montesinos P (2024) A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold? Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-024-05891-w","journal-title":"Ann Hematol"},{"issue":"18","key":"6543_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184618","volume":"15","author":"A Ucciero","year":"2023","unstructured":"Ucciero A, Pagnoni F, Scotti L, Pisterna A, Barone-Adesi F, Gaidano G et al (2023) Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of survival data from real-world studies. Cancers (Basel) 15(18):4618","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6543_CR40","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1002\/ajh.26846","volume":"98","author":"A Candoni","year":"2023","unstructured":"Candoni A, Lazzarotto D, Papayannidis C, Piccini M, Nadali G, Dargenio M et al (2023) Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first\u2010line therapy with hypomethylating agents alone or in combination with venetoclax. Am J Hematol 98(4):E80\u2013E83","journal-title":"Am J Hematol"},{"issue":"5","key":"6543_CR41","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.21873\/anticanres.17003","volume":"44","author":"Y Baba","year":"2024","unstructured":"Baba Y, Hida N, Sambe T, Abe M, Kabasawa N, Sakai H et al (2024) Efficacy of venetoclax and azacitidine in acute myeloid leukemia compared to azacitidine monotherapy: real-world experience. Anticancer Res 44(5):2003\u20132007","journal-title":"Anticancer Res"},{"issue":"1","key":"6543_CR42","doi-asserted-by":"publisher","first-page":"2343604","DOI":"10.1080\/16078454.2024.2343604","volume":"29","author":"H He","year":"2024","unstructured":"He H, Wen X, Zheng H (2024) Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis. Hematology 29(1):2343604","journal-title":"Hematology"},{"issue":"20","key":"6543_CR43","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S et al (2019) Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv 3(20):2911\u20132919","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06543-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06543-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06543-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:12Z","timestamp":1761283812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06543-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6543"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06543-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"30 August 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}